Recent 8-K filings for CRVS

• August 6, 2026, 4:02 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Corvus reports Q2 2026 net loss of $18.0M; cash $215.2M, runway into 2Q28

  Net loss $18.0M in Q2 2026 vs $8.0M in Q2 2025; R&D expenses $16.0M vs $7.9M.

• July 22, 2026, 4:02 PM ET leadership materiality 0.35 neutral item 5.02

  Director Ian T. Clark resigns from Corvus board effective July 22, 2026

  Ian T. Clark delivered notice of resignation from the Board on July 21, 2026, effective July 22, 2026.

• June 12, 2026, 4:01 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Corvus stockholders re-elect Miller, Grais; ratify PwC as FY 2026 auditor

  Richard A. Miller and Linda S. Grais elected as Class I directors with 58.3M and 53.2M votes for, respectively; 12.0M broker non-votes.

• May 14, 2026, 7:01 AM ET other material materiality 0.65 positive item 7.01item 8.01item 9.01

  Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; durable remissions without rebound

  72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus reports Q1 2026 net loss of $13.7M; cash $236.7M; soquelitinib trials advance

  Net loss $13.7M in Q1 2026 vs net income $15.2M in Q1 2025; cash $236.7M (incl. $189.4M from Jan 2026 financing).

• April 23, 2026, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

  Corvus Pharmaceuticals appoints Andrew C. Chan to board; Scott Morrison resigns

  Andrew C. Chan appointed as Class II director, effective April 23, 2026, term through 2027 annual meeting.

• March 13, 2026, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  Corvus ups at-the-market equity facility to $200M from $100M

  Amended Sales Agreement with Jefferies allows up to $200M in common stock sales, increased from $100M.

• March 12, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M

  Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).

• January 23, 2026, 6:59 PM ET other material materiality 0.80 neutral item 8.01item 9.01

  Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds

  Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.

• January 20, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026

  Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.

• January 20, 2026, 6:59 PM ET other material materiality 0.40 neutral item 8.01

  Corvus Pharmaceuticals suspends $100M ATM equity offering program

  Suspended $100M at-the-market offering; zero shares sold prior to suspension.

• November 4, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing

  Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.

• October 2, 2025, 7:59 PM ET leadership materiality 0.25 neutral item 5.02

  David Moore joins Corvus board as Class III director through 2028; gets 30K option grant

  David Moore appointed as Class III director, term expires at 2028 annual meeting.

• August 7, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction

  Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).

• June 13, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Corvus Pharmaceuticals 2025 Annual Meeting results: all proposals approved

  Elected Class III directors Ian T. Clark (28.9M for, 10.4M withheld) and Peter A. Thompson (38.8M for, 0.4M withheld).

• June 4, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Corvus soquelitinib Phase 1 atopic dermatitis data show statistically significant EASI improvement vs placebo

  Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 8.01item 9.01

  Corvus Q1 net income $15.2M; soquelitinib atopic derm cohort 3 EASI −71.1% vs placebo −42.1%

  Net income of $15.2M included $25.1M gain on warrant liability; R&D spend $7.5M vs $4.1M YoY.

• April 9, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Corvus Pharmaceuticals appoints Richard van den Broek to Board, effective April 8, 2025

  Richard van den Broek appointed as Class II director, term expiring at 2027 annual meeting.

• March 25, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Corvus reports Q4 net loss $12.1M, cash $52M; atopic dermatitis Phase 1 shows 37% EASI 75 vs 0% placebo

  Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.

• January 13, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo

  19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.

• December 18, 2024, 6:59 PM ET other material materiality 0.78 positive item 7.01item 8.01item 9.01

  Corvus reports positive interim Phase 1 soquelitinib data in atopic dermatitis; $12.7M warrant exercise

  Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.

• November 12, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024

  Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.

• October 23, 2024, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 9.01

  Corvus Pharmaceuticals enters sub-sublease for 20,916 sq ft in South San Francisco

  Sublease term of 36 months from later of consent or Feb 1, 2025; option to extend up to May 2030.

• August 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track

  Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.

• June 14, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Corvus shareholders elect Scott Morrison to board, ratify PwC, approve exec pay

  Scott W. Morrison elected Class II director with 19,667,286 votes for, 5,398,946 withheld.

• May 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing

  Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.

• May 6, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation

  Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit

• May 1, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Corvus cuts ATM program ceiling from $90M to $8.2M; nearly all capacity used

  Amendment reduces aggregate offering price under Jefferies ATM from $90M to $8.2M.

• March 19, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus Q4 net loss $6.7M; soquelitinib Orphan Drug; Phase 3 PTCL trial on track

  Net loss $6.7M in Q4 2023 vs $9.8M Q4 2022; cash $27.1M at Dec 31, 2023.

• January 23, 2024, 6:59 PM ET leadership materiality 0.20 neutral item 5.02item 8.01item 9.01 ◈ executive_change

  Corvus Pharmaceuticals announces death of board member Edith P. Mitchell

  Board member Dr. Edith P. Mitchell passed away; she served on Corvus board since September 2020.

• November 7, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus reports Q3 net loss $6.0M, cash $32.2M; soquelitinib Phase 3 trial protocol finalized

  Net loss $6.0M vs $14.8M in Q3 2022; R&D expenses down to $4.0M from $10.4M.

• September 7, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Corvus confirms soquelitinib Phase 3 trial for PTCL; initiation Q1 2024

  FDA End-of-Phase meeting completed; trial design confirmed: 150 patients, 1:1 randomization, primary endpoint PFS.

• August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus reports Q2 net loss $6.5M, soquelitinib shows 3 CR/3 PR in TCL; plans FDA meeting

  Soquelitinib Phase 1/1b: 3 complete, 3 partial responses in 20 evaluable TCL patients.

• June 21, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Corvus Pharmaceuticals holds 2023 annual meeting; elects directors and ratifies auditor

  Stockholders elected Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. as Class I directors for three-year terms.

• May 8, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus reports Q1 net loss of $7.9M; CPI-818 shows 6/13 ORR in ALC>900 TCL patients

  Net loss of $7.9M vs $8.3M in Q1 2022; cash & securities $34.5M as of March 31, 2023.

• April 24, 2023, 7:59 PM ET regulatory materiality 0.60 positive item 8.01

  Corvus Pharmaceuticals regains Nasdaq minimum bid price compliance

  Received Nasdaq deficiency notice on Oct 25, 2022 for bid price below $1.00.

• April 3, 2023, 7:59 PM ET other material materiality 0.40 neutral item 5.02

  Corvus Pharma reduces CEO salary from $300K to $34,840; grants 800K options

  CEO base salary cut to $34,840/year effective March 31, 2023, from $300,000.

• March 29, 2023, 7:59 PM ET other material materiality 0.30 neutral item 1.02 ◈ Material Agreements

  Corvus terminates ATM equity programs with Jefferies

  Terminated 2020 Sales Agreement (up to $50M) and 2021 Sales Agreement (up to $40M) with Jefferies LLC effective March 28, 2023.

• March 28, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus reports Q4 net loss of $9.8M; identifies predictive biomarker for CPI-818 in T-cell lymphoma

  Cash $42.3M at Dec 31, 2022 (from $69.5M); 2023 operating burn guided $19-22M with year-end cash $20-23M.

• March 13, 2023, 7:59 PM ET other material materiality 0.60 positive item 7.01

  Corvus Pharmaceuticals confirms no cash or securities at Silicon Valley Bank

  Corvus Pharmaceuticals, on March 10, 2023, stated it does not hold cash deposits or securities at Silicon Valley Bank.

• November 3, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Corvus adopts annual advisory say-on-pay vote after stockholder vote

  Board sets annual frequency for non-binding advisory votes on executive compensation.

• November 3, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Corvus Q3 net loss $14.8M; cash $49.6M, CPI-818 data at ASH

  Net loss $14.8M for Q3 2022 vs $10.7M Q3 2021; R&D expense $10.4M (+$3.4M).

• October 28, 2022, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  Corvus Pharma receives Nasdaq delisting notice for bid price below $1.00

  Nasdaq notified Corvus on Oct 25, 2022 that its stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.

• August 8, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Corvus prioritizes CPI-818; pauses mupadolimab Phase 2; Q2 net loss $8.4M

  Cash, cash equivalents and marketable securities $56.7M as of June 30, 2022, down from $69.5M at Dec 31, 2021.

• June 17, 2022, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Corvus shareholders elect all director nominees, ratify auditor, approve say-on-pay

  Elected Class III directors: Ian T. Clark (20.9M for), Elisha Gould III (22.6M for), Peter Thompson (17.1M for).

• May 5, 2022, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Corvus Pharma Q1 net loss $8.3M; cash $62.9M; Phase 2 NSCLC trial planned

  Net loss $8.3M for Q1 2022 vs $11.6M in Q1 2021; R&D expenses down to $5.1M from $8.2M.

• March 10, 2022, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Corvus reports Q4 net loss of $9.2M, cash $69.5M; plans Phase 2 trials in NSCLC and RCC

  Net loss Q4 2021 $9.2M vs net income $27.3M in Q4 2020 (incl $37.5M deconsolidation gain).

• November 2, 2021, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  Corvus enters $40M ATM equity offering with Jefferies LLC

  Sales agreement for up to $40M in common stock, Jefferies as sales agent.

• November 1, 2021, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  Corvus Q3 net loss $10.7M, cash $76.3M; mupadolimab trials enrolling

  Net loss for Q3 2021 was $10.7M vs $9.8M in Q3 2020; R&D expenses $7.0M vs $6.6M.

• August 2, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Corvus Q2 net loss $11.8M; discontinues COVID-19 trial, cuts cash burn guidance

  Cash, equivalents and marketable securities $66.5M at June 30, 2021, up from $44.3M at Dec 31, 2020.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.60 · Most common event earnings

14 positive 1 negative 35 neutral

source · CRVS on sec.gov